How arsenic affects cancer development in the bladder
Redox and Protein Homeostasis in Arsenic Tumorigenicity
This study is looking at how arsenic, a harmful substance, can lead to bladder cancer by affecting a protein that helps our cells handle stress, and it hopes to find new ways to prevent and treat this type of cancer, which could help patients understand their risks better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11013043 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which arsenic, a known carcinogen, contributes to the development of bladder cancer. It focuses on the role of a protein called NRF2, which helps cells respond to stress, and how arsenic disrupts normal cellular processes to promote tumor growth. By examining the interactions between arsenic and cellular proteins, the study aims to uncover new insights into cancer biology that could lead to better prevention and treatment strategies. Patients may benefit from understanding how arsenic exposure relates to their cancer risk and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of arsenic exposure or those diagnosed with bladder cancer.
Not a fit: Patients who do not have a history of arsenic exposure or who are not diagnosed with bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating bladder cancer associated with arsenic exposure.
How similar studies have performed: Other research has shown promising results in understanding the role of NRF2 in cancer biology, indicating that this approach may yield valuable insights.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Chapman, Eli — University of Florida
- Study coordinator: Chapman, Eli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.